Clinical Trials Corner
Open Access
- 20 January 2018
- journal article
- editorial
- Published by SAGE Publications in Bladder Cancer
- Vol. 4 (1) , 133-136
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- JAMA OncologyJAMA Oncology, 2017
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology, 2017
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialThe Lancet, 2017
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016